Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
If approved, DTX401 would be the first treatment to address the disease at its root cause
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Subscribe To Our Newsletter & Stay Updated
